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Background. National VL Elimination Programs in India, Nepal and Bangladesh face challenges as home-based Miltefosine
treatment is introduced. Objectives. To study constraints of VL management in endemic districts within context of national
elimination programs before and after intervention. Methods. Ninety-two and 41 newly diagnosed VL patients were interviewed
for clinical and provider experience in 2009 before and in 2010 after intervention (district training and improved supply of
diagnostics and drugs). Providers were assessed for adherence to treatment guidelines. Facilities and doctor-patient consultations
were observed to assess quality of care. Results. Miltefosine use increased from 33% to 59% except in Nepal where amphotericin
was better available. Incorrect dosage and treatment interruptions were rare. Advice on potential side eﬀects was uncommon but
improved significantly in 2010. Physicians did not rule out pregnancy prior to starting Miltefosine. Fever measurement or spleen
palpation was infrequently done in Bangladesh but improved after intervention (from 23% to 47%). Physician awareness of renal
or liver toxicity as Miltefosine side eﬀects was lower in Bangladesh. Bio-chemical monitoring was uncommon. Patient satisfaction
with services remained low for ease of access or time provider spent with patient. Health facilities were better stocked with rK39
kits and Miltefosine in 2010.
1. Introduction
Visceral Leishmaniasis (VL) or Kala-azar has a high-disease
burden in endemic districts of the Indian subcontinent
(annual VL incidence ranging from 9/10,000 in Nepal to
30/10,000 pop. in India and Bangladesh) [1]. These VL
endemic countries have adopted a range of public health
strategies towards the elimination goal of reducing VL cases
to less than 1/10,000 population by 2015 [2]. Kala-azar
Elimination Programs (KAEP) aim to reduce VL morbidity
and mortality by early detection, diagnosis, and treatment of
VL through strengthening diagnostic and treatment facilities
at peripheral health care institutions and referral services.
These coupled with integrated vector management strategies
including indoor residual spraying, promotion of use of
insecticide treated bed nets aim to reduce VL transmission
and disease burden. Despite eﬀorts, disease transmission
continues. Early detection is hindered by a surveillance
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system which is primarily dependent on passive reporting of
patients to a public health facility. Surveillance systems rarely
capture VL cases treated in the private sector. Furthermore
PKDL cases escape detection through routine surveillance
and contribute to continued transmission of the disease in
the community [3]. Many VL cases go undiagnosed in a
web of unqualified medical practitioners before they are
finally diagnosed and treated for VL in the qualified private
or public health sector leading to considerable delays in
diagnosis and treatment [1, 4]. Recent studies show that
active case detection strategies increase early VL detection
and reduce delays to diagnosis and treatment [5, 6]. Early
diagnosis is now feasible with the increasing use of field-
based rapid diagnostic tests (rK39) to detect antibodies
to recombinant antigen rK39 which are highly sensitive
(range 98%-99%) and specific (range 96%-97%) [7]. Drugs
available for VL treatment are limited with no new drugs
under development. Historically, antimonials have been the
primary line of treatment but now face emerging problems
of drug resistance. Amphotericin B deoxycholate used more
often as a secondary line of treatment for VL cases respond-
ing poorly to antimonials requires prolonged hospitalization
and repeated biochemical monitoring. Miltefosine, the only
oral drug for VL, has been recently favoured as it is
highly eﬀective (94% cure rate) with minimal side eﬀects
[8–11]. Recent research has shown single-dose liposomal
Amphotericin B as well as combination drug therapy to be
highly eﬀective and safe but it will take some years before it
can be adopted by country control programs.
WHO TDR has supported a research program to de-
termine disease burden, identify, and test strategies for
early detection and treatment of VL since 2006. In 2009
(preintervention phase), researchers identified VL patients
using active case detection strategies. In 2010, Kala-azar
Elimination Program (KAEP) staﬀ was trained in these
strategies and in VL case management according to national
guidelines [12–14] accompanied by an increased procure-
ment of diagnostics and drugs through the national program.
This paper looks at the pre- and postintervention prospects
and constraints of VL management from a patient and
provider perspective in VL endemic districts of India, Nepal,
and Bangladesh within the context of KAEP activities.
2. Material and Methods
2.1. Ethics Statement. The research programwas approved by
the Ethics Committees of all participating research institutes
and the Ethics Review Committee of the WHO. Patients and
health care providers participated in the study after providing
a written informed consent.
2.2. Study Area and VL Treatment Policies. The study was
conducted in districts of Saran and Muzaﬀarpur in India,
Sarlahi,Mahottari, andDhanusha inNepal andMymensingh
in Bangladesh. The VL endemicity level in these districts
varied from an annual incidence of 20–25 per 10,000 in
India, 5–8 per 10,000 in Nepal, and 13–31 per 10,000 in
Bangladesh. Disease surveillance has been largely passive and
predominantly dependent on patients reporting to public
health facilities. Antimonials as first and Amphotericin B
as second line was the mainstay of VL treatment until
2009. Though Miltefosine was available in the private sector
in India earlier, it was introduced free of cost through
the VL elimination program as first line of treatment
India in 2009. In Nepal it became available in 2007 and
Bangladesh in 2010. Rapid diagnostic tests (rK39) for VL
have been available in district hospitals in Nepal since 2005,
at Primary Health Centers in India in 2009, and in Upazila
Health Complex (sub-district hospital) in Bangladesh since
2010.
2.3. Identifying New Cases of VL and Training for Improved
Application of National Treatment Guidelines; Preintervention
and Program Intervention Phase. In 2009 (preintervention
phase), four active case detection strategies (camp approach,
index case approach—focal house search around known VL
case, incentive approach, and blanket approach—house-to-
house search) were assessed for yield of new VL cases by
researchers [6]. The most cost-eﬀective of these active case
detection strategies (camp approach in high VL endemic
areas and index case approach in low-to-moderate VL
endemic areas) was presented to the intercountry Regional
Technical Advisory Group (RTAG) and then introduced as
part of the VL elimination program in 2010. Standard Oper-
ating Procedures were developed and program managers,
doctors, and health workers were trained and supported by
the researchers in the planning of these active case detection
strategies. A total of 243 health staﬀ was trained across
all sites in active case detection strategies and VL case
management as per country guidelines. The health system
adopted these active case detection strategies to identify new
VL cases in 2010 and reinforced the procurement of VL
diagnostics and drugs in peripheral health facilities while the
training program—jointly developed by national program
managers and the research team and supported by German
cooperation (Federal Ministry for Economic Cooperation
and Development (BMZ)/Gesellschaft fu¨r Internationale
Zusammenarbeit (GIZ) GmbH—focussed at the correct
application of national treatment guidelines (program inter-
vention package). A total of 126 health workers and volun-
teers in India, 91 in Nepal, and 26 in Bangladesh were trained
in active case detection strategies and home-based VL case
management.
As per the research protocol, all newly identified VL pa-
tients through active case detection in 2009 who were treated
with Miltefosine were interviewed by researchers at the end
of their treatment for their clinical experience, their inter-
action and experiences with providers using a standardized
pretested questionnaire. The Indian site additionally chose
to interview newly identified VL patients treated with other
than Miltefosine. Whereas in 2010, all newly identified VL
patients were interviewed irrespective of their drug treatment
by all sites. We compare treatment patterns and patient
perspectives before and after the intervention.
Patient satisfaction with provider care was rated on a 5-
point scale using a shortened 18-item version of the Patient
Journal of Tropical Medicine 3
Satisfaction Questionnaire (PSQ-18) [15]. Patient satisfac-
tion mean score (range 1 to 5) in several domains was
derived with high scores reflecting high satisfaction levels.
Additionally, interactions between patients and providers
were directly observed in a structured manner by researchers
wherever feasible.
Providers were also interviewed with a standardized
questionnaire to assess their knowledge and experiences of
treating VL, adherence to treatment guidelines and their per-
ception of home treatment with Miltefosine. Health facilities
were assessed (structured spot inspection) for availability of
diagnostic kits and drugs, records and equipment required to
treat VL and side eﬀects.
We compare means and proportions for various patient
and provider characteristics for diﬀerences seen in 2009 and
2010 separately for each site. Due to small samples of VL
patients and providers, we used Fischer’s exact test to test for
significance of diﬀerences not disaggregated by site.
3. Results
A total of 92 (India-63; Nepal-8; Bangladesh-21) new VL
patients were identified through these active case detection
strategies (camps, focal search around index case, etc.)
in 2009 and 41 (India-8; Nepal-20; Bangladesh-13) in
2010. Thirteen newly diagnosed VL patients in 2009 from
Bangladesh were thought to be cases of VL relapse and
were referred to the district hospital for further treatment.
We were not able to ascertain the treatment status of these
patients as they were lost to follow-up. Patients were sig-
nificantly younger (mean age 22 years, SD-16.47) in 2010
compared to 33 years (SD-15.9) in 2009 (P value= 0.009).
The proportion of women was significantly higher (32% in
2010 compared to 8% in 2009; P value= 0.027).
3.1. VL Patient Experiences: Preintervention and Program
Intervention Phase. Overall, the proportion of VL patients
treated with Miltefosine as 1st line of treatment increased
from 33% in 2009 to 59% in 2010 (Table 1) except in
Nepal where it decreased from 38% to 20%. In contrast,
use of SAG as primary treatment decreased from 53% in
2009 to 2% in 2010. Amphotericin B was the mainstay of
treatment in Nepal (63% in 2009; 80% in 2010). One patient
from India in 2009 received an incorrect dosage schedule
of VL treatment. Furthermore, treatment was interrupted
in 1 patient in India in 2009 and 1 each in India (due
to side eﬀects) and Nepal (due to drug shortage) in 2010.
Overall, 3% and 10% patients experienced side eﬀects in
2009 and 2010, respectively—the increase in minor side
eﬀects (diarrhea and vomiting) was seen to parallel increased
use of Miltefosine. All patients reported that they received
advice from their doctors regarding need to comply with
treatment. In contrast, doctor’s advice on possibility of drug
side eﬀects during treatment was received by only 8% of
patients in 2009—this increased to 63% in 2010. A similar
increase (61% in 2009 to 76% in 2010) was seen for receiving
doctor’s advice on need to comply with follow-up visits
during treatment.
3.2. VL Treatment Practices and Infrastructure: Quality Aspects
of Treatment Care. A total of 31 (India: 23; Nepal: 3;
Bangladesh: 5) initial and 30 (India: 13; Nepal: 0; Bangladesh:
17) follow-up doctor consultations were observed in 2009
and 53 (India-23; Nepal-12; Bangladesh-18) initial and 20
(India-0; Nepal-0; Bangladesh-20) follow-up doctor consul-
tations in 2010 (Table 2). Overall, doctors asked for family
history of VL in about 68% of initial consultations in 2009
and 72% in 2010. Doctors in India were least likely (57%
in 2009 and 48% in 2010) to ask for family history of
VL in contrast to Bangladesh where all doctors asked for
family history of VL. Only about 1 in 6 (17%) doctors
in Nepal asked for history to rule out pregnancy before
starting Miltefosine. In contrast, 71% (in 2009) and 100%
(in 2010) of doctors in India ruled out pregnancy on history.
Almost all doctors advised drug dosage based on the patient’s
weight and age. Measurement of patient’s temperature and
palpation for spleen size to reconfirm the initial diagnosis
made by physicians at the case detection camps and for
monitoring treatment recovery was done in 51% in 2009 and
63% and 73% in 2010, respectively. This was least likely in
Bangladesh (23% in 2009 and 47% in 2010), while in India,
this increased from 64% in 2009 to 100% in 2010. Doctors
advised testing patient’s blood for haemoglobin level in less
than half of the consultations observed both in 2009 and
2010. Again, doctors in Bangladesh were least likely to advise
testing during treatment (14% in 2009 increasing marginally
to 32% in 2010). In Nepal, the proportion of doctors asking
for family history of VL, advising drug dosage based on
patient’s weight, measurement of patient’s temperature, and
advice for testing blood during treatment was lower in 2010
compared to 2009. Overall, a substantial increase (47% in
2009 to 95% in 2010) was seen in doctors inquiring for
side eﬀects during follow-up visits. This increase was most
marked in Bangladesh (6% in 2009, 95% in 2010).
Overall, patient satisfaction in all aspects of care in-
creased significantly in 2010 compared to 2009 (Table 3)
except for a marginal nonsignificant decrease of satisfaction
in the amount of time provider spent with the patient.
Patient satisfaction score was highest for general and tech-
nical aspects of care (4.11 in 2009; 4.43 in 2010), provider
manners (3.19 in 2009; 4.25 in 2010) and level of provider
communication (3.21 in 2009; 4.17 in 2010) but was lower
for provider access (2.933 in 2009; 3.68 in 2010), and time
spent by provider with the patient (3.70 in 2009; 3.56
in 2010). Patient satisfaction for general aspects of care,
provider manners and communication, ease of provider
access and time spent by provider, financial aspects of care
was lower in Bangladesh in 2009 but became comparable
with India and Nepal in 2010.
Overall, health care facilities were better stocked with
rK39 diagnostic kits in 2010 (9 of 9 and 5 of 8 health facilities
inspected in India and Nepal, resp.) compared to 2009 (7 of
13 in India and 0 of 2 in Nepal) (Figure 1). In contrast, 4 of
4 health facilities had rK39 kits stocked in 2009 compared
to only 1 of 4 in 2010 in Bangladesh. Similarly, Miltefosine
stocks were available in 6 of 13 and 0 of 4 health facilities in
2009 compared to 9 of 9 and 3 of 4 health facilities in 2010 in
India and Bangladesh, respectively. In contrast, 2 of 2 health
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Table 1: VL case management: patient experiences.
India Nepal Bangladesh Overall
2009 2010 2009 2010 2009 2010 2009 2010
No. of new VL cases detected 63 8 8 20 212 13 92 41
No. of VL cases started with (%)
(i) SAG
34/63
(54%)
1/8
(13%)
0/8
(0%)
0/20
(0%)
8/8
(100%)
0/13
(0%)
42/79
(53%)
1/41
(2%)
(ii) Amphotericin B
6/63
(10%)
0/8
(0%)
5/8
(63%)
16/20
(80%)
0/8
(0%)
0/13
(0%)
11/79
(14%)
16/41
(39%)
(iii) Miltefosine
23/63
(37%)
7/8
(88%)
3/8
(38%)
4/20
(20%)
0/8
(0%)
13/13
(100%)
26/79
(33%)
24/41
(59%)
No. of VL cases given correct dosage
schedule (%)
62/63
(98%)
8/8
(100%)
3/3
(100%)
20/20
(100%)
8/8
(100%)
13/13
(100%)
73/74
(99%)
41/41
(100%)
No. of VL cases with treatment
interrupted (%)
1/63
(2%)
1/8
(13%)
(side eﬀect)
0/3
(0%)
1/20
(5%)
(no drug)
0/8
(0%)
0/13
(0%)
1/74
(1%)
2/41
(5%)
No. VL cases experiencing side eﬀects (%)
2/63
(3%)
1/8
(13%)
0/3
(0%)
1/20
(5%)
0/8
(0%)
2/13
(15%)
2/74
(3%)
4/41
(10%)
No. VL cases received doctor’s
advice on (%)
(i) Need to comply with
treatment (%)
63/63
(100%)
8/8
(100%)
3/3
(100%)
20/20
(100%)
—3
13/13
(100%)
66/66
(100%)
41/41
(100%)
(ii) Side eﬀects (%)
2/63
(3%)
8/8
(100%)
3/3
(100%)
6/20
(30%)
—2
12/13
(92%)
5/66
(8%)
26/41
(63%)
(iii) Compliance with follow up (%)
37/63
(59%)
8/8
(100%)
3/3
(100%)
11/20
(55%)
—2
12/13
(92%)
40/66
(61%)
31/41
(76%)
Did you comply with FU advise
37/63
(59%)
8/8
(100%)
3/3
(100%)
7/20
(35%)
—2
12/13
(92%)
40/66
(61%)
27/41
(66%)
Volunteer support for home treatment
with Miltefosine (%)
15/23
(65%)
4/7
(57%)
3/3
(100%)
3/4
(75%)
NA4
4/13
(31%)
18/26
(69%)
11/24
(46%)
2
13 patients were diagnosed as relapse of VL and referred to district hospital. Treatment status could not be ascertained subsequently.
3Information on doctor advice to patients is not captured in Bangladesh in the interview for patients who received other than Miltefosine treatment.
4Not applicable as no patient received Miltefosine.
Table 2: VL management practices: observation of doctor patient consultations.
India Nepal Bangladesh Overall
2009 2010 2009 2010 2009 2010 2009 2010
No. of doctor-patient consultations
observed: 1st visit
(n = 23) (n = 23) (n = 3) (n = 12) (n = 5) (n = 18) (n = 31) (n = 53)
Follow-up visit (n = 13) (n = 0) (n = 0) (n = 0) (n = 17) (n = 20) (n = 30) (n = 20)
(i) Doctor asked patient for family
h/o VL at 1st visit
13/23
(57%)
11/23
(48%)
3/3
(100%)
9/12
(75%)
5/5
(100%)
18/18
(100%)
21/31
(68%)
38/53
(72%)
(ii) Doctor asked about pregnancy
at 1st visit of women of
reproductive age
5/7
(71%)
6/6
(100%)
—
1/6
(17%)
1/1
(100%)
—
6/8
(75%)
7/12
(58%)
(iii) Doctor advised drug dose
based on patient’s weight
at 1st visit
22/23
(96%)
23/23
(100%)
3/3
(100%)
10/12
(83%)
5/5
(100%)
18/18
(100%)
30/31
(97%)
51/53
(96%)
(iv) Temperature of patient was
measured
23/36
(64%)
23/23
(100%)
3/3
(100%)
5/12
(42%)
5/22
(23%)
18/38
(47%)
31/61
(51%)
46/73
(63%)
(v) Doctor examined patient for
spleen enlargement
23/36
(64%)
23/23
(100%)
3/3
(100%)
12/12
(100%)
5/22
(23%)
18/38
(47%)
31/61
(51%)
53/73
(73%)
(vi) Doctor advised blood tests for
patient
21/36
(58%)
20/23
(87%)
3/3
(100%)
5/12
(42%)
3/22
(14%)
12/38
(32%)
27/61
(44%)
37/73
(51%)
(vii) On FU visit, doctor asked
patient for side eﬀects
13/13
(100%)
— — —
1/17
(6%)
19/20
(95%)
14/30
(47%)
19/20
(95%)
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Table 3: Patient satisfaction with medical care (significant diﬀerences in patient satisfaction scores between 2009 and 2010 in boldface).
India Nepal Bangladesh Overall
2009 2010 2009 2010 2009 2010 2009 2010
(n = 60) (n = 8) (n = 3) (n = 225) (n = 8) (n = 13) (n = 71) (n = 43)
Mean patient satisfaction score (SD)
(i) General aspects of care
4.20
(0.944)
4.56
(0.903)
4.50
(0.000)
4.38
(0.858)
3.31
(0.530)
4.42
(0.534)
4.11
(0.931)
4.43
(0.768)
(ii) Technical aspects of care
3.62
(0.557)
4.09
(0.421)
3.41
(0.144)
4.37
(0.538)
3.71
(0.507)
4.23
(0.494)
3.62
(0.539)
4.27
(0.506)
(iii) Provider manner
3.32
(0.573)
4.62
(0.517)
3.33
(0.577)
4.15
(0.543)
2.12
(0.991)
4.19
(0.830)
3.19
(0.728)
4.25
(0.648)
(iv) Level of provider
communication
3.20
(0.576)
3.87
(1.093)
4.33
(0.288)
4.25
(0.550)
2.87
(0.640)
4.23
(0.632)
3.21
(0.624)
4.17
(0.697)
(v) Financial aspects of care
2.61
(0.820)
3.31
(0.593)
3.83
(0.288)
4.02
(0.892)
2.31
(1.412)
3.57
(0.812)
2.63
(0.917)
3.75
(0.854)
(vi) Time spent by provider
3.96
(1.149)
3.93
(0.821)
2.16
(0.288)
3.36
(0.639)
2.31
(0.593)
3.69
(0.878)
3.70
(1.238)
3.56
(0.768)
(vii) Ease of provider access
3.05
(0.590)
3.59
(0.376)
3.7
(0.000)
3.88
(0.413)
1.68
(0.513)
3.38
(0.976)
2.93
(0.734)
3.68
(0.657)
5
Includes 2 nonstudy VL patients.
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Figure 1: Health care facility (HCF) infrastructure to diagnose and
treat VL.
facilities had Miltefosine stocks in 2009 compared to only 4
of 8 in 2010 in Nepal. None of the health facilities inspected
in Bangladesh had stocks of Amphotericin B in both 2009
and 2010. Overall, there was no significant diﬀerence (P
value= 0.349) in the proportion of health facilities keeping
patient specific VL treatment cards in 2009 (63%) compared
to 2010 (57%).
3.3. Provider Perspectives on VL Management and Adherence
to Guidelines. A total of 30 (India: 19, Nepal: 7, and
Bangladesh: 4) and 27 (India: 21, Nepal: 2, and Bangladesh:
4) physicians were interviewed in 2009 and 2010, respectively
(Table 4). All physicians in Nepal and Bangladesh used rK39
test results as basis for starting VL treatment while in India
18 of 19 in 2009 and 13 of 21 physicians in 2010 used
rK39 test to initiate VL treatment. Overall, Miltefosine was
preferred for VL treatment by 73% of physicians in 2009
increasing to 93% in 2010. In India, 89% physicians in
2009 and 95% in 2010 reported Miltefosine use in their
practice, while Amphotericin B use decreased from 58% in
2009 to 14% in 2010. Less than 50% physicians reported
SAG use in both 2009 and 2010. In Nepal, physician use for
Miltefosine and Amphotericin B was same (71% in 2009)
(50% in 2010). In Bangladesh, physicians used antimonials
(SAG) for VL treatment in 2009 and Miltefosine when it
became available in 2010. Safety and availability of drug were
the most important criteria for physician’s choice of drug
for VL treatment in all sites. In Bangladesh, aﬀordability and
eﬀectiveness of the drug were equally important criteria for
physician’s drug choice. In India, 63% physicians in 2009
and 57% in 2010 reported they advised blood tests before or
during treatment. In Bangladesh, this proportion fell from
100% in 2009 to 50% in 2010. The most common reasons
for not advising blood tests were either because the physician
felt there was no need or there was no laboratory technician
available to do the blood tests. In Nepal, all physicians
reported advising a blood test during VL treatment. Overall,
physician awareness of side eﬀects ofMiltefosine was lower in
Bangladesh. Physician awareness of diarrhea or vomiting was
high in India (100%) and Nepal (71% in 2009 and 100% in
2010). Physician awareness of other side eﬀects ofMiltefosine
like jaundice (0%) and teratogenicity (40%) was lower in
2009 and increased marginally in 2010. A higher proportion
of physicians recommended home-based treatment with
Miltefosine in 2010 (93%) compared to 2009 (60%) except
in Nepal where 1 of 2 (50%) physicians recommended home
treatment in 2010 compared to 5 of 7 (71%) in 2009. Almost
all physicians in India, Nepal, and Bangladesh in 2010 felt
that Miltefosine treatment under direct observation at home
would be eﬀective.
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Table 4: Physician perspectives of VL management.
India Nepal Bangladesh Overall
2009 2010 2009 2010 2009 2010 2009 2010
No. of physicians interviewed (n = 19) (n = 21) (n = 7) (n = 2) (n = 4) (n = 4) (n = 30) (n = 27)
Rk39 test as decision criteria to treat VL
18/19
(95%)
13/21
(62%)
7/7
(100%)
2/2
(100%)
4/4
(100%)
4/4
(100%)
29/30
(97%)
19/27
(70%)
Physician’s use of VL drug
(i) SAG
8/19
(42%)
10/21
(48%)
0/7
(0%)
0/2
(0%)
4/4
(100%)
4/4
(100%)
12/30
(40%)
14/27
(52%)
(ii) Amphotericin B
11/19
(58%)
3/21
(14%)
5/7
(71%)
1/2
(50%)
0/4
(0%)
0/4
(0%)
16/30
(53%)
4/27
(15%)
(iii) Miltefosine
17/19
(89%)
20/21
(95%)
5/7
(71%)
1/2
(50%)
0/4
(0%)
4/4
(100%)
22/30
(73%)
25/27
(93%)
Physician criteria for VL drug selection
(i) Available
14/19
(74%)
19/21
(90%)
4/7
(57%)
2/2
(100%)
4/4
(100%)
3/4
(75%)
22/30
(73%)
24/27
(89%)
(ii) Aﬀordable
8/19
(42%)
11/21
(52%)
1/7
(14%)
0/2
(0%)
4/4
(100%)
3/4
(75%)
13/30
(43%)
14/27
(52%)
(iii) Safe
18/19
(95%)
21/21
(100%)
4/7
(57%)
1/2
(50%)
4/4
(100%)
3/4
(75%)
26/30
(87%)
25/27
(93%)
(iv) Eﬀective
12/19
(63%)
12/21
(57%)
4/7
(57%)
1/2
(50%)
4/4
(100%)
3/4
(75%)
20/30
(67%)
16/27
(59%)
No. physician advises blood tests (%)?
12/19
(63%)
12/21
(57%)
7/7
(100%)
2/2
(100%)
4/4
(100%)
2/4
(50%)
23/30
(77%)
16/27
(59%)
Reason for not advising blood tests?
No need
4/7
(57%)
— — — —
1/2
(50%)
4/7
(57%)
1/11
(9%)
No lab technician —
9/9
(100%)
— — —
1/2
(50%)
—
10/11
(91%)
No. physician aware of Miltefosine side
eﬀects (%)
(i) Diarrhea
19/19
(100%)
21/21
(100%)
5/7
(71%)
2/2
(100%)
0/4
(0%)
0/4
(0%)
24/30
(80%)
23/27
(85%)
(ii) Vomiting
19/19
(100%)
21/21
(100%)
5/7
(71%)
2/2
(100%)
0/4
(0%)
3/4
(75%)
24/30
(80%)
26/27
(96%)
(iii) Jaundice
0/19
(0%)
12/21
(57%)
0/7
(0%)
1/2
(50%)
0/4
(0%)
1/4
(25%)
0/30
(0%)
14/27
(52%)
(iv) Abdominal pain
5/19
(26%)
9/21
(43%)
1/7
(14%)
2/2
(100%)
0/4
(0%)
3/4
(75%)
6/30
(20%)
14/27
(52%)
(v) Renal toxicity
14/19
(74%)
4/21
(19%)
2/7
(29%)
1/2
(50%)
0/4
(0%)
0/4
(0%)
16/30
(53%)
5/27
(19%)
(vi) Teratogenicity
11/19
(58%)
11/21
(52%)
1/7
(14%)
1/2
(50%)
0/4
(0%)
0/4
(0%)
12/30
(40%)
12/27
(44%)
No. physician recommend home based
Miltefosine treatment (%)
10/19
(53%)
20/21
(95%)
5/7
(71%)
1/2
(50%)
3/4
(75%)
4/4
(100%)
18/30
(60%)
25/27
(93%)
No. physician feel home-based
Miltefosine treatment is eﬀective (%)?
15/19
(79%)
20/21
(95%)
6/7
(86%)
2/2
(100%)
1/4
(25%)
4/4
(100%)
22/30
(73%)
26/27
(96%)
Despite Miltefosine being available free of cost to the
patient through the program, 12% of the health workers
interviewed in Bangladesh perceived the cost of VL treatment
to be aﬀordable, while 18% perceived it to be too high. A
majority of health staﬀ felt that lack of patient awareness and
lack of access to facility (100% in India; 82% in Bangladesh)
were major challenges to early detection and diagnosis of VL.
Drug shortage and lack of patient compliance were perceived
by health workers to be major barriers to VL treatment
in India. About half of all health workers in India and
Bangladesh reported cost as a barrier to VL treatment. In
India, 64% of health workers reported occurrence of drug-
related side eﬀects as a problem for VL treatment compared
to 18% of health workers in Bangladesh.
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4. Discussion
In the preintervention phase (2009), VL patients were diag-
nosed using rK39 tests conducted by the researchers. These
newly diagnosed VL cases were then referred to health centers
and their further treatment was ensured by the researchers.
In contrast, in 2010, the researchers’ role was restricted to
training of trainers in the health system in home-based VL
management with Miltefosine applying national treatment
guidelines. Diagnosis and home-based treatment of VL cases
under direct observation of a health functionary or volunteer
in 2010 was fully the responsibility of the health system
(program intervention phase). The researchers assessed the
availability of diagnostics and drugs in peripheral health
facilities and evaluated VL case management as implemented
by the health system.
The use of antimonials showed a dramatic decline
in 2010 as preference shifted towards Miltefosine as the
primary line of VL treatment—in Bangladesh, this shift was
consequent to introduction of Miltefosine in the country
while in India it was more due to its availability in the public
sector at no cost to the patient. In Nepal, at the time of
the study Amphotericin B continued to be used as the drug
of choice for VL treatment in 2010 as one of the district
hospital had to dispense a large stock before its expiry. Also,
Amphotericin B was preferred by physicians at one of the
zonal hospitals.
The shift towards Miltefosine was paralleled by an
increase in the known side eﬀects of Miltefosine (diarrhea
and vomiting) but a decrease in side eﬀects from antimo-
nials (not documented in this study). Almost all patients
received the correct dosage schedule in both study phases
indicating correct prescription practices and a high level
of knowledge about drug dosage and schedules amongst
physicians. Treatment was interrupted in less than 5% of
patients in either phase (in one patient due to drug shortage).
Miltefosine dosage schedule is based on the patient’s age and
body weight. Its use is contraindicated in infants, pregnant,
or breast-feeding women or women of reproductive age
group unless counselled to prevent pregnancy with use of
oral contraceptives [12]. A pregnancy test is also generally
recommended to rule out pregnancy prior toMiltefosine use.
Medical supervision is advised twice a week and monitoring
for hepatic and renal function is recommended wherever
feasible according to national guidelines. Counselling for
need to comply with full treatment seemed to be adequate
in both study phases. Counselling for need to follow up
weekly during treatment was lower in 2009 but increased in
the postintervention phase especially in India. Counselling
of patients on potential side eﬀects was still inadequate and
needs to be strengthened. Only about 1 in 6 physicians
in Nepal ruled out pregnancy on history in women of
reproductive age. Pregnancy test or contraceptive counselling
was not done for any woman of reproductive age prior to
Miltefosine use. The quality of care given by providers was
inadequate. Fever was measured in less than half of initial
or follow-up visits in Nepal and Bangladesh. Spleen size was
assessed by palpation in less than half of initial or follow-
up visits in Bangladesh. Blood tests (biochemical monitoring
before and during treatment) were advised in less than half
of all initial or follow-up visits in Nepal and Bangladesh.
Monitoring of side eﬀects during follow-up visits was almost
universal in the postintervention phase. Though there was
a significant improvement in patient satisfaction levels in
the postintervention phase, patients were less satisfied with
ease of access to provider and the time spent by the provider
with them. Generally patients in India were more satisfied
with how providers communicated with them as well as
their manners and attitudes in the postintervention phase
compared to patients in Nepal and Bangladesh. However,
these diﬀerences in satisfaction levels could be cultural based
on patient’s experiences and expectations of health services.
Overall, health facilities were better stocked with rK39
diagnostic kits and VL drugs in 2010 except in Bangladesh
where 3 of the 4 health facilities inspected did not have
rK39 diagnostic kits. Drug supply was available and adequate
in health facilities in India. Amphotericin B as 2nd line of
treatment was not available in more than half of all health
facilities in India and Nepal and not at all available in
Bangladesh. Drug supply needs to be strengthened especially
in Nepal and Bangladesh. The maintenance of patient
specific treatment cards needs to be strengthened at all health
facilities in each country.
In summary, physician counselling practices requires
to be strengthened. Despite availability, about one-third of
physicians (especially in the private sector) in India still
rely on tests other than rK39 for VL diagnosis. Physician
choice is driven by the availability of the drug and its
perceived safety and less so by aﬀordability or eﬀectiveness
of the drug. Ensuring an adequate drug supply will greatly
influence physician prescription practice for VL. Physician
awareness of the common side eﬀects of Miltefosine like
diarrhea and vomiting is high. However, awareness about
important but less common side eﬀects of Miltefosine like
liver and renal toxicity is low especially in Bangladesh and
needs to be improved. Testing blood for haemoglobin, liver,
and renal function before and during VL treatment is still
not routine practice with physicians in India and Bangladesh.
Improving physician awareness of potential side eﬀects of
Miltefosine and ensuring availability of laboratory services
will strengthen physician practice of routine bio-chemical
monitoring before and during VL treatment. National
guidelines stipulate that Miltefosine can be administered at
home under direct supervision of a health volunteer/health
functionary. Though almost all physicians in India, Nepal,
and Bangladesh feel that home-based treatment of VL with
Miltefosine is eﬀective, only about half the physicians in
Nepal would recommend it.
5. Conclusion
Though limited by small samples of patients interviewed and
doctor-patient consultations observed and health facilities
inspected, our study provides evidence on constraints and
prospects of VL management in VL endemic districts
of India, Nepal, and Bangladesh when implemented by
national VL elimination programs. This underlines the need
8 Journal of Tropical Medicine
for continued operational research to direct the Kala-azar
elimination programme.
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